Beyond MEN1, when to think about MEN4? Retrospective study on 5600 patients in the French population & literature review.
Benjamin ChevalierLucie CordiezPauline RomanetThomas CunyJean-Christophe MaïzaJuliette AbeillonJulien ForestierThomas WalterOlivier GillyMaelle Le BrasSarra SmatiMarie Laure NunesAurore GeslotSolange GrunenwaldCéline MoulyGwenaelle ArnaultKathy WagnerEugénie KoumakisChristine Cortet-RudelliÉmilie MerlenArnaud JanninStéphanie EspiardIsabelle MorangeÉric BaudinMathias CavailleIgor TauveronMarie-Pierre TeissierFrançoise Borson-ChazotDelphine PrunierFrédérique SavagnerÉric PasmantSophie GiraudMarie-Christine VantyghemPierre GoudetAnne BarlierCatherine Cardot-BautersMarie-Françoise OdouPublished in: The Journal of clinical endocrinology and metabolism (2024)
The prevalence of MEN4 is low. PHPT and PA represent the main associated lesions, NETs are rare. Our results suggest a milder and later phenotype than in MEN1. Our observations will help to improve genetic counseling and management of MEN4 families.